Identification of the von Hippel-Lindau (VHL) gene, as most frequently deleted gene in RCC cells, accelerated development of vascular endothelial growth factor (VEGF)-targeted therapy for treatment of the disease. This evidence concerns the gene VHL and renal cell adenocarcinoma.